Volume 18, Number 10—October 2012
Dispatch
Orthobunyavirus Antibodies in Humans, Yucatan Peninsula, Mexico
Table
Endpoint titers of serum samples collected from persons in Mexico and analyzed by using comparative PRNT*
Patient ID no. |
Demographic characteristics
|
PRNT90 titers
|
Diagnosis | |||||||
---|---|---|---|---|---|---|---|---|---|---|
Residence | Age, y/sex | CVV | CHLV | KRIV | SOURV | MAGV | WYOV | |||
28 | Yucatan | 18/M | 80 | 20 | – | – | 40 | – | UND | |
34 | Yucatan | 39/F | 80 | 20 | – | – | 20 | – | CVV | |
52 | Quintana Roo | 39/F | 160 | – | – | 40 | 80 | – | UND | |
54 | Yucatan | 32/M | 40 | 20 | – | – | 40 | – | UND | |
62 | Yucatan | 44/M | 40 | – | – | 20 | 20 | – | UND | |
72 | Yucatan | 23/M | 80 | – | – | – | 40 | – | UND | |
81 | Yucatan | 60/F | 20 | 20 | – | 20 | – | – | UND | |
92 | Yucatan | 13/M | 160 | 20 | – | 20 | 80 | – | UND | |
93 | Yucatan | 42/F | 40 | 20 | – | – | 20 | – | UND | |
113 | Yucatan | 24/F | 20 | – | – | – | – | – | UND | |
114 | Yucatan | 29/F | 40 | – | – | – | 20 | – | UND | |
120 | Yucatan | 60/F | 20 | – | – | 320 | – | – | SOURV or SOURV-like virus | |
159 | Yucatan | 54/M | 20 | – | – | – | 20 | – | UND | |
161 | Yucatan | 53/M | 20 | 20 | – | – | – | – | UND | |
163 | Yucatan | 27/F | 160 | 80 | 40 | – | 40 | – | UND | |
167 | Yucatan | 16/M | 160 | – | – | – | 40 | – | CVV | |
183 | Yucatan | 69/F | 20 | – | – | – | 20 | – | UND | |
184 | Yucatan | 34/M | 160 | 40 | – | – | 80 | – | UND | |
185 | Yucatan | 25/F | 20 | – | – | – | – | – | UND | |
192 | Campeche | 54/F | 80 | 40 | – | – | 20 | – | UND | |
193 | Yucatan | 16/F | 80 | – | – | – | 20 | – | CVV | |
194 | Yucatan | 69/F | 20 | – | – | 20 | – | – | UND | |
200 | Yucatan | 3/F | 40 | – | – | 40 | 40 | – | UND | |
205 | Yucatan | 53/M | 40 | – | – | 20 | 20 | – | UND | |
208 | Yucatan | 57/F | 20 | 160 | – | – | – | – | CHLV | |
210 | Yucatan | 42/M | 20 | – | – | – | 20 | – | UND | |
224 | Yucatan | 34/M | 20 | 20 | – | 20 | – | – | UND | |
234 | Yucatan | 39/F | 20 | 80 | – | – | 20 | – | CHLV | |
236 | Yucatan | 74/F | 20 | – | – | 20 | – | – | UND | |
386 | Yucatan | 14/F | 20 | – | – | 20 | – | – | UND | |
388 | Yucatan | 60/M | 160 | 1,280 | 160 | – | 40 | – | CHLV | |
389 | Yucatan | 5/M | 20 | – | – | 20 | – | – | UND | |
390 | Yucatan | 33/M | 40 | 20 | 40 | 20 | 40 | – | UND | |
392 | Yucatan | 22/M | 20 | – | – | – | – | – | UND | |
393 | Yucatan | 29/M | 40 | 20 | – | – | 40 | – | UND | |
396 | Yucatan | 34/F | 80 | – | – | – | 20 | – | CVV | |
397 | Yucatan | 32/M | 80 | – | – | – | 40 | – | UND | |
399 | Yucatan | 27/M | 320 | 1,280 | 160 | – | 320 | – | CHLV | |
400 | Yucatan | 37/F | 20 | – | – | – | – | – | UND | |
401 | Yucatan | 30/F | 160 | – | – | – | 40 | – | CVV | |
402 | Yucatan | 18/M | 20 | – | – | – | 20 | – | UND | |
403 | Yucatan | 50/F | 20 | 20 | – | – | – | – | UND | |
407 | Yucatan | 27/M | 80 | 20 | – | – | 40 | – | UND | |
408 | Yucatan | 40/F | 20 | – | – | – | – | – | UND | |
412 | Yucatan | 60/M | 20 | 320 | 80 | 40 | 40 | – | CHLV | |
415 | Yucatan | 17/F | 20 | – | – | 20 | – | – | UND | |
420 | Yucatan | 16/F | 160 | – | – | – | 20 | – | CVV | |
429 | Yucatan | 37/F | 20 | – | – | – | – | – | UND | |
442 | Yucatan | 10/F | 20 | 40 | – | 20 | – | – | UND | |
455 | Yucatan | 30/F | 20 | – | – | 20 | 20 | – | UND |
*PRNT, plaque reduction neutralization test; CVV, Cache Valley virus; CHLV, Cholul virus; KRIV, Kairi virus; SOURV, South River virus; MAGV, Maguari virus, WYOV, Wyeomyia virus; –, titer <20; UND, undetermined orthobunyavirus.
Page created: September 14, 2012
Page updated: September 14, 2012
Page reviewed: September 14, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.